Peter Drucker Society Europe Appoints Sunil Prashara of Project Management Institute to International Advisory Board
1.4.2021 18:00:00 EEST | Business Wire | Press release
Project Management Institute (PMI) and the Peter Drucker Society Europe today announced the launch of a strategic partnership in which PMI President and CEO Sunil Prashara will join the Drucker Society International Advisory Board.
The Peter Drucker Society Europe is a non-profit organization that seeks to advance a critical, international dialogue between management practitioners, academics, and other stakeholders. Their mission is to give a new voice to management in all sectors of society, thus contributing to the continuous improvement of the practice of management. This partnership will complement PMI’s role as the world's leading association for project professionals and changemakers.
“Both organizations are non-profit entities with the shared objective of improving the practice of management in every area of society, from government and public sector to private and not-for-profit bodies,” said Richard Straub, founder and president of the Global Peter Drucker Forum, the annual conference organized by the Drucker Society Europe.
“We are enabling millions of project leaders and changemakers to make important contributions to the world,” Prashara said. “PMI’s mission—to enable individuals to make ideas reality—aligns perfectly with Peter Drucker’s legacy of rigorous thought leadership around management as a systematic discipline entailing research, teaching, and practice. I see the Drucker Forum as a key platform and partner for raising awareness of the fundamental importance of management in building functioning modern societies.”
In support of their mission, the Peter Drucker Society Europe has designated the Global Peter Drucker Forum as a strategic initiative. The forum is an international management conference held annually in Peter Drucker's home city of Vienna, Austria, and is often hailed as the "Davos of Management,” as it has become one of the leading management conferences in Europe. The Global Peter Drucker Forum 2021 is centered on the theme of “The Human Imperative: Navigating Uncertainty in the Digital Age.” Forum stakeholders will take part in a range of discussion on ways to resolve tensions between technocratic and humanistic approaches to crisis, to arrive at a synthesis of "change and continuity."
###
About Project Management Institute
Project Management Institute (PMI) is the world's leading professional association for a growing global community of millions of project professionals and changemakers worldwide.
As the world’s leading authority on project management, PMI empowers people to make ideas a reality. Through global advocacy, networking, collaboration, research, and education. PMI prepares organizations and individuals at every stage of their career journey to work smarter so they can drive success in a world of change.
Building on a proud legacy dating to 1969, PMI is a “for-purpose” organization working in nearly every country around the world to advance careers, strengthen organizational success, and enable changemakers with new skills and ways of working to maximize their impact. PMI offerings include globally recognized standards, certifications, online courses, thought leadership, tools, digital publications, and communities.
Visit us at https://www.pmi.org/, www.projectmanagement.com , https://www.linkedin.com/company/pminstitute , www.facebook.com/PMInstitute , and on Twitter.
About Peter Drucker Society Europe Initiative
The Peter Drucker Society Europe is a practitioner-led, multi-stakeholder group that builds on Peter Drucker’s fundamental ideas and ideals with the aim of contributing to the evolution of management as a vital piece of a functioning modern society. Each year, the Drucker Society Europe hosts the Global Peter Drucker Forum, a crystallizing event where decision makers convene to discuss the future of management in a pragmatic and solution-oriented manner.
To fulfil its mission, the Peter Drucker Society Europe has established legally and financially independent nonprofit Drucker Society chapters in Austria, London, Barcelona and Mannheim. Please note that The Drucker 1996 Literary Works Trust is the owner of the service marks "Peter Drucker", "Peter F. Drucker" and "Drucker".
Learn more at www.druckerforum.org
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210401005059/en/
Contact information
PMI Contact:
David Summers | mobile:(610) 930-3425
press@pmi.org
Drucker Forum Contact:
www.druckerforum.org/contact/
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom